NASDAQ:CTXR

Citius Pharmaceuticals Stock Forecast, Price & News

$1.80
+0.10 (+5.88 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.70
Now: $1.80
$1.84
50-Day Range
$1.51
MA: $1.85
$2.07
52-Week Range
$0.69
Now: $1.80
$2.90
Volume5.43 million shs
Average Volume12.36 million shs
Market Capitalization$226.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677
Employees10
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.61 per share

Profitability

Net Income$-17,550,000.00

Miscellaneous

Market Cap$226.41 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

Headlines

Leonard Mazur
April 8, 2021 |  benzinga.com
What Awaits Citius Pharma In 2021?
February 22, 2021 |  nasdaq.com
See More Headlines

MarketRank

Overall MarketRank

1.29 out of 5 stars

Medical Sector

833rd out of 2,024 stocks

Pharmaceutical Preparations Industry

395th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$1.80
+0.10 (+5.88 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

Is Citius Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Citius Pharmaceuticals stock.
View analyst ratings for Citius Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Citius Pharmaceuticals?

Wall Street analysts have given Citius Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Citius Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Citius Pharmaceuticals?

Citius Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,030,000 shares, an increase of 51.3% from the March 15th total of 7,290,000 shares. Based on an average trading volume of 13,810,000 shares, the short-interest ratio is currently 0.8 days.
View Citius Pharmaceuticals' Short Interest
.

When is Citius Pharmaceuticals' next earnings date?

Citius Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Citius Pharmaceuticals
.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its quarterly earnings data on Wednesday, February, 10th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.16 by $0.31.
View Citius Pharmaceuticals' earnings history
.

How has Citius Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Citius Pharmaceuticals' stock was trading at $0.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTXR stock has increased by 200.0% and is now trading at $1.80.
View which stocks have been most impacted by COVID-19
.

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Citius Pharmaceuticals's stock reverse split on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CTXR?

2 brokerages have issued 1 year price objectives for Citius Pharmaceuticals' stock. Their forecasts range from $4.00 to $6.00. On average, they anticipate Citius Pharmaceuticals' stock price to reach $5.00 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for Citius Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the following people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 76, Pay $410k)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 74, Pay $735k)
  • Mr. Jaime Bartushak, CFO & Chief Accounting Officer (Age 53, Pay $440k)
  • Dr. Myron S. Czuczman M.D., Exec. VP & Chief Medical Officer (Age 62, Pay $436.42k)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 66)
  • Mr. Andrew Scott, VP of Corp. Devel.

Who are some of Citius Pharmaceuticals' key competitors?

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

Who are Citius Pharmaceuticals' major shareholders?

Citius Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Horst & Graben Wealth Management LLC (0.04%). Company insiders that own Citius Pharmaceuticals stock include Leonard L Mazur and Myron Z Holubiak.
View institutional ownership trends for Citius Pharmaceuticals
.

Which major investors are buying Citius Pharmaceuticals stock?

CTXR stock was acquired by a variety of institutional investors in the last quarter, including Horst & Graben Wealth Management LLC. Company insiders that have bought Citius Pharmaceuticals stock in the last two years include Leonard L Mazur, and Myron Z Holubiak.
View insider buying and selling activity for Citius Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.80.

How much money does Citius Pharmaceuticals make?

Citius Pharmaceuticals has a market capitalization of $226.41 million.

How many employees does Citius Pharmaceuticals have?

Citius Pharmaceuticals employs 10 workers across the globe.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is www.citiuspharma.com.

Where are Citius Pharmaceuticals' headquarters?

Citius Pharmaceuticals is headquartered at 11 Commerce Drive First Floor, Cranford NJ, 07016.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.


This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.